Cover Image
市场调查报告书

非小细胞肺癌:全球临床实验趋势

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2018

出版商 GlobalData 商品编码 229164
出版日期 内容信息 英文 3085 Pages
订单完成后即时交付
价格
Back to Top
非小细胞肺癌:全球临床实验趋势 Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2018
出版日期: 2018年03月31日 内容信息: 英文 3085 Pages
简介

本报告提供非小细胞肺癌相关之临床研究最新趋势分析,提供您疾病·治疗方法概要,及G7及E7各国的临床实验状况,各地区、各阶段的进行状况,并汇整有潜力的赞助商,各企业及研究机关的研究进行状况,有潜力的药剂比较等信息。

本报告概要

各地区的临床实验情形

  • 各国临床实验数量和平均实验人数
    • 前五名国家的临床实验数量; 亚太地区
    • 前五名国家的临床实验数量; 欧洲
    • 主要国家的临床实验数量; 北美
    • 前五名国家的临床实验数量; 中东/非洲地区
    • 前五名国家的临床实验数量; 中南美

G7各国的临床实验数量:非小细胞肺癌临床实验数量占肿瘤临床实验数量比率

各期临床实验数量: G7各国

G7各国的临床实验数量:各期

E7各国的临床实验数量:非小细胞肺癌临床实验数量占肿瘤临床实验数量比率

各期临床实验数量: E7各国

E7各国的临床实验数量:各期

各期临床实验数量

  • 各期的进展中临床实验数量

各进展状况临床实验数量

各评估项目临床实验数量

一定期间所采用的受验人数

赞助商类别的临床实验数量

有潜力的赞助商

临床实验主要参加企业 - 非小细胞肺癌治疗药

有潜力的药剂

最新临床实验新闻:非小细胞肺癌

临床实验简介的基本数据

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GDHC4884CTIDB

GlobalData's clinical trial report, "Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Non-Small Cell Lung Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Small Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 5
  • List of Figures 6
  • Report Guidance 7
  • GlobalData Clinical Trials Report Coverage 8
  • Clinical Trials by Region 9
  • Clinical Trials and Average Enrollment by Country 10
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Five Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 18
  • Clinical Trials in G7 Countries by Trial Status 19
  • Clinical Trials by E7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 20
  • Clinical Trials by Phase in E7 Countries 21
  • Clinical Trials in E7 Countries by Trial Status 22
  • Clinical Trials by Phase 23
  • In Progress Trials by Phase 24
  • Clinical Trials by Trial Status 25
  • Clinical Trials by End Point Status 26
  • Subjects Recruited Over a Period of Time 27
  • Clinical Trials by Sponsor Type 28
  • Prominent Sponsors 29
  • Top Companies Participating in Non-Small Cell Lung Cancer Therapeutics Clinical Trials 30
  • Prominent Drugs 31
  • Latest Clinical Trials News on Non-Small Cell Lung Cancer 32
  • Apr 10, 2018: BerGenBio Completes Recruitment Into First Stage of Phase II NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA 32
  • Apr 10, 2018: Spectrum Pharmaceuticals Announces Update of MD Anderson's Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients 32
  • Apr 09, 2018: NICE gives Green Light to New Immunotherapy for most Common form of Lung Cancer 32
  • Apr 09, 2018: KEYTRUDA (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor Cells 33
  • Apr 09, 2018: G1 Therapeutics to Present Preclinical Data on G1T38 at the 2018 American Association for Cancer Research (AACR) Annual Meeting 33
  • Apr 05, 2018: Molecular Partners to present MP0310 pre-clinical data at the AACR Annual Meeting 2018 34
  • Apr 05, 2018: Molecular Partners to present MP0250 clinical abstract at the AACR Annual Meeting 2018 34
  • Apr 04, 2018: Loxo Oncology Announces Acceptance of LOXO-292 Oral Presentation at the American Society of Clinical Oncology Annual Meeting 34
  • Apr 04, 2018: Vaccibody as Announces Informed Consent Signed by First Patient and Enrollment Process Initiated in the Cancer Neoantigen Phase I/IIA Clinical Trial 35
  • Apr 02, 2018: Lung cancer drug shows promise as targeted therapy for thousands with breast cancer 35
  • Mar 22, 2018: BerGenBio to present overview of phase II clinical trial portfolio combining bemcentinib with KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe 36
  • Mar 22, 2018: Oncology Venture Sweden: Scientific Journal Highlights Study Of The Drp Tool In Cisplatin Treatment For Patients With Lung Cancer 36
  • Mar 19, 2018: Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Squamous Lung Cancer 37
  • Mar 15, 2018: OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment 38
  • Mar 14, 2018: Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018 38
  • Mar 14, 2018: First-Line Lung Cancer Data and Other New Research from Merck's Broad Oncology Program to be Presented at AACR Annual Meeting 38
  • Mar 14, 2018: TESARO to Present Data on Oncology Product Candidate TSR-042 at AACR 2018 Annual Meeting 40
  • Mar 14, 2018: Research from Bristol-Myers Squibb's Innovative Oncology Development Program to Be Presented at AACR 2018 Demonstrates Commitment to Advancing Precision Medicine Research for Patients with Cancer 40
  • Mar 12, 2018: AstraZeneca Provides Update on MYSTIC Trial Timeline 42
  • Mar 12, 2018: Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer 42
  • Feb 28, 2018: Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer 43
  • Feb 27, 2018: OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment 43
  • Feb 23, 2018: L-DOS47 US Phase I Study Presentation at the IASLC 18th Annual Target Therapies of Lung Cancer Meeting 43
  • Feb 22, 2018: Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer 44
  • Feb 15, 2018: Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer 44
  • Feb 14, 2018: Heat Biologics Announces Poster Presentation of Interim Phase 2 Lung Cancer Clinical Data for HS-110 and Nivolumab at the 2018 Keystone Symposia Conference XI: Immunological Memory: Innate, Adaptive and Beyond 45
  • Feb 13, 2018: Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer 45
  • Feb 07, 2018: Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer 46
  • Feb 07, 2018: Xcovery Announces Initiation of Phase 2 Clinical Trial for Ensartinib in Melanoma Patients with ALK Alternations 47
  • Feb 05, 2018: Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer Patients with High Tumor Mutation Burden 47
  • Jan 31, 2018: Puma Biotechnology Announces Publication of Results from Phase II SUMMIT 'Basket' Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancer 48
  • Jan 30, 2018: Heat Biologics to Host Analyst and Investor Event February 28, 2018 to Present Results from its Phase 2 Lung Cancer Study 48
  • Jan 23, 2018: Biomarck Announces the Start of a Phase 2 Clinical Trial of BIO-11006 for Non-Small Cell Lung Cancer 49
  • Jan 16, 2018: First Patient Dosed in a Phase 2 Trial with Transgene TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC) 49
  • Jan 16, 2018: Merck's KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment in Combination with Pemetrexed and Platinum Chemotherapy for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (KEYNOTE-189) 50
  • Clinical Trial Profile Snapshots 51

Appendix 3082

  • Abbreviations 3082
  • Definitions 3082
  • Research Methodology 3083
  • Secondary Research 3083
  • About GlobalData 3084
  • Contact Us 3084
  • Disclaimer 3084
  • Source 3085

List of Tables

List of Tables

  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region, 2018* 9
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 10
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 11
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 12
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 13
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries, 2018* 14
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 15
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 16
  • Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2018* 17
  • Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
  • Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
  • Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2018* 20
  • Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 21
  • Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 22
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase, 2018* 23
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 24
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2018* 25
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2018* 26
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 27
  • Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 28
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 29
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 30
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 31

List of Figures

List of Figures

  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region (%), 2018* 9
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 10
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 11
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 12
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 13
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 14
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 15
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 16
  • Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2018* 17
  • Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
  • Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
  • Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2018* 20
  • Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 21
  • Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 22
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2018* 23
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 24
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2018* 25
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2018* 26
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 27
  • Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 28
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 29
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 30
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 31
  • GlobalData Methodology 3083
Back to Top